MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes

This therapy consists of autologous T lymphocytes genetically engineered to express a chimeric antigen receptor (CAR) containing the single-chain variable fragment (scFv) derived from the mouse monoclonal antibody clone MFE-23, which specifically targets carcinoembryonic antigen (CEA). The construct typically includes intracellular signaling domains such as CD28 and CD3ζ. Upon administration, these modified T cells recognize and bind to CEA-expressing tumor cells via the scFv domain. Engagement with CEA triggers activation signals through the CD3ζ and costimulatory domains in the engineered T cell, leading to cytokine release, proliferation of effector functions, and direct cytotoxicity against tumor cells expressing CEA. This approach is being investigated primarily for solid tumors that overexpress CEA—including colorectal cancer and other advanced malignancies[2][3][5]. The therapy is an example of adoptive cell transfer immunotherapy using a second-generation CAR design.

Other names

Anti-CEA (MFE-23) CAR-T cellsAnti-CEA (MFE23) h(CD28-CD3ζ) CAR-T cells